Insys Therapeutics has agreed to pay $150 million to settle a case with the Department of Justice regarding sales of a powerful opioid.
According to the criminal and civil investigation, the company paid kickbacks to doctors who prescribed their under-the-tongue spray product, Subsys.
Under the terms of the settlement, Insys will pay $150 million over five years and then may need to make additional payments of up to $75 million, depending on certain unspecified circumstances.
“This is a very important step for our company to move forward and continue our transformative efforts to foster a compliant and ethical culture,” the company’s CEO, Saeed Motahari, said.
Read the full Bloomberg report.